Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H32N2O2 |
Molecular Weight | 356.5017 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(O)C=C(CCNCCCCCCNCCC2=CC=CC=C2)C=C1
InChI
InChIKey=RYBJORHCUPVNMB-UHFFFAOYSA-N
InChI=1S/C22H32N2O2/c25-21-11-10-20(18-22(21)26)13-17-24-15-7-2-1-6-14-23-16-12-19-8-4-3-5-9-19/h3-5,8-11,18,23-26H,1-2,6-7,12-17H2
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/1970288
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1970288
Dopexamine hydrochloride is a synthetic catecholamine, structurally related to dopamine, with marked intrinsic agonist activity at beta 2-adrenoceptors, lesser agonist activity at dopamine DA1- and DA2-receptors and beta 1-adrenoceptors, and an inhibitory action on the neuronal catecholamine uptake mechanism. The drug is administered by intravenous infusion, and is characterized by a rapid onset and short duration of action. Dopexamine is being tested as a treatment for heart failure and sepsis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/1363232 |
|||
Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1363232 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of dopexamine on hepatic metabolic activity in patients with septic shock. | 2001 Jun |
|
Impairment of renal function after cardiopulmonary bypass is not influenced by dopexamine. | 2001 Mar |
|
Effects of dobutamine and dopexamine on hepatic micro- and macrocirculation during experimental endotoxemia: an intravital microscopic study in the rat. | 2001 Mar |
|
Effects of dopexamine on acute necrotising pancreatitis in rats. | 2001 Oct |
|
Attenuation of lung inflammation by adrenergic agonists in murine acute lung injury. | 2001 Oct |
|
Dopexamine but not dopamine increases gastric mucosal oxygenation during mechanical ventilation in dogs. | 2002 Apr |
|
Dopexamine attenuates microvascular perfusion injury of the small bowel in pigs induced by extracorporeal circulation. | 2002 Jun |
|
Haemodynamic effects of dopexamine on postprandial splanchnic hyperaemia. | 2004 Apr |
|
Effect of adding dopexamine to intraoperative volume expansion in patients undergoing major elective abdominal surgery. | 2004 Apr |
|
Effects of dopexamine on rat cardiorenal functions during lipopolysaccharide-induced experimental sepsis. | 2004 Mar-Apr |
|
Optimal management of the high risk surgical patient: beta stimulation or beta blockade? | 2005 |
|
Highs and lows in high-risk surgery: the controversy of goal-directed haemodynamic management. | 2005 |
|
Dopexamine and its role in the protection of hepatosplanchnic and renal perfusion in high-risk surgical and critically ill patients. | 2005 Apr |
|
Hemodynamic monitoring over the past 10 years. | 2006 Feb |
|
Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury. | 2006 Feb |
|
Year in review 2006: Critical Care--Multiple organ failure, sepsis, and shock. | 2007 |
|
Heme oxygenase-1 induction in the brain during lipopolysaccharide-induced acute inflammation. | 2008 Jun |
|
Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. | 2009 |
|
Gastric tonometry versus cardiac index as resuscitation goals in septic shock: a multicenter, randomized, controlled trial. | 2009 |
|
The effect of fenoldopam and dopexamine on hepatic blood flow and hepatic function following coronary artery bypass grafting with hypothermic cardiopulmonary bypass. | 2009 Jun |
|
Is dopexamine superior to dopamine in the treatment of multiple trauma patients--a prospective, double-blind, randomised study. | 2010 May |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8850384
0.5 ug/kg/min (heart failure), from 0.5 ug/kg/min with 0.5 ug/kg/min increments every 3 min (septic shock).
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1363232
[3H]-Dopexamine was specifically bound to sections of human right or left ventricle. The binding was time-, temperature- and concentration-dependent and was dissociable. The apparent equilibrium constant of dissociation was 3·5 nM. A decreased [3H]-dopexamine binding capacity from the base to the apex and ventricles was noticeable.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C01CA14
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
||
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
||
|
WHO-VATC |
QC01CA14
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C046318
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
55483
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
948
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
100000080763
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
86197-47-9
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
m4742
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | Merck Index | ||
|
23638
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | RxNorm | ||
|
Dopexamine
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
398E7Z7JB5
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
CHEMBL77622
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
DTXSID2048666
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
5455
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
W-98
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
C75039
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
SUB06366MIG
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY | |||
|
DB12313
Created by
admin on Fri Dec 15 16:11:26 GMT 2023 , Edited by admin on Fri Dec 15 16:11:26 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)